Vessi Medical

Vessi Medical takes a new approach to treat superficial bladder cancer. The Company uses surface cryotherapy, a treatment that utilizes extreme cold, to freeze and destroy abnormal tissue.

The Vessi Medical Opportunity

The market seeks an effective treatment for superficial bladder cancer that offers reduced recurrence rates, improved patient outcomes, and lower health care costs.

Vessi Medical’s Novel Solution

Vessi Medical takes a new approach in the treatment of superficial bladder cancer. The Company uses surface cryotherapy, a treatment that utilizes extreme cold, to freeze and destroy abnormal tissue. The Vessi Medical system consists of a standalone console and a disposable catheter that is inserted into the bladder similarly to existing intravesical techniques.


  • Proven high efficacy rate (for surface lesions)
  • Reduced side effects
  • Inexpensive solution

Currently, dermatologists and gynecologists use surface cryotherapy extensively, and it has been known to be highly effective in destroying surface lesions.


Founded: Joined Trendlines Medical July 2017
Stage: Technology development
Investor: The Trendlines Group
IP: National phase and provisional

The Team

  • Eyal Kochavi, CEO: 14 years’ experience in bringing medical device products to the market, in particular in the cryotherapy and urology fields; prior positions include VP R&D and Business Development Project Manager and Director R&D; MBA and M.Sc. (cum laude), Technion-Israel Institute of Technology
  • Moti Simchon, Senior Engineer: 45 years’ experience in pneumatics, fine mechanics, and cryogenics; proven out-of-the-box thinker
  • Prof. Gilad E. Amiel, Scientific Advisor: Chairman, Department of Urology, Rambam Health Care Campus, Israel; adjunct Associate Professor of Urology, Baylor College, Houston, Texas; former President of the American Association for Cancer Education (AACE); member of the American Urological Association (AUA) and several other professional organizations
  • Doron Birger, Business Advisor: Former President and CEO, Elron; former Chairman, Given Imaging; chairman and board member of numerous medical device companies

Background & Market

Non-muscle-invasive bladder cancer (NMIBC), also known as superficial bladder cancer, is found on the surface of the inside lining of the bladder, and accounts for ~75% of new patients with bladder cancer. In cases of high-risk superficial bladder cancer, treatment involves intravesical (inside the bladder) therapy in which an immunotherapy or chemotherapy drug is inserted directly into the bladder via a catheter. These therapy modalities cause severe side effects and have limited outcomes. Unfortunately, due to high recurrence rates, many patients undergo bladder removal.

Reports state that bladder cancer has the highest cost per patient of all cancers, and that 43% of all bladder removals begin with superficial cancer (European Association of Urology. 2012. Guidelines on Bladder Cancer Muscle-invasive and Metastatic.)

At any point in time, an estimated 3 million people worldwide have a history of bladder cancer. The World Cancer Research Fund International estimates there are about 430,000 new bladder cancer cases worldwide each year. In the U.S. alone, about 79,000 new cases are diagnosed annually (American Cancer Society).

The Company estimates its global market potential at over $1 billion annually.

Vessi Medical logo
Cryotherapy for superficial bladder cancer


Eyal Kochavi, CEO

Font Resize